Brian Cormier
Medical · Escalon, CANPI 1407045586
Payments from drug & device makers
Across 169 payments — averaging $18.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$584
- AbbVie$344
- Boehringer Ingelheim$282
- AstraZeneca$261
- Pfizer$222
- Johnson & Johnson$205
- plus $1K from 22 others
What the payments were for
- Food & beverage$2,99497%
- Education$833%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 32 | $584 |
| AbbVie | 27 | $344 |
| Boehringer Ingelheim | 17 | $282 |
| AstraZeneca | 7 | $261 |
| Pfizer | 16 | $222 |
| Johnson & Johnson | 10 | $205 |
| Novo Nordisk | 9 | $173 |
| Lilly USA, LLC | 7 | $150 |
| Mylan Specialty L.p. | 7 | $148 |
| Amgen | 6 | $127 |
| Neurocrine Biosciences, Inc. | 4 | $77 |
| Corcept Therapeutics | 3 | $60 |
| Forte Bio-pharma LLC | 1 | $53 |
| E.r. Squibb & Sons, L.L.C. | 3 | $49 |
| Sunovion Pharmaceuticals Inc. | 4 | $46 |
| Biohaven Pharmaceuticals, Inc. | 2 | $46 |
| UCB, Inc. | 2 | $31 |
| Sanofi-aventis U.S. LLC | 2 | $27 |
| Alkermes, Inc. | 1 | $24 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $22 |
| Hikma Pharmaceuticals USA | 1 | $21 |
| Dexcom, Inc. | 1 | $21 |
| Xeris Pharmaceuticals, Inc. | 1 | $20 |
| Acadia Pharmaceuticals Inc | 1 | $19 |
| Merck | 1 | $18 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $18 |
| Bayer | 1 | $16 |
| Amarin Pharma, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TRELEGY ELLIPTA$125
- XARELTO$117
How this compares
$3,077 in reported general payments places this provider in the 80th percentile of 2,087 medical providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 186 | $165,552 |
| EliquisApixaban | 101 | $77,539 |
| OzempicSemaglutide | 65 | $72,256 |
| SynjardyEmpagliflozin/Metformin Hcl | 92 | $64,637 |
| JanumetSitagliptin Phos/Metformin Hcl | 52 | $58,866 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 90 | $57,558 |
| FarxigaDapagliflozin Propanediol | 43 | $46,681 |
| Invega SustennaPaliperidone Palmitate | 12 | $40,318 |
| TrulicityDulaglutide | 30 | $30,100 |
| LinzessLinaclotide | 30 | $24,118 |
| Wellbutrin XlBupropion Hcl | 12 | $21,426 |
| JanuviaSitagliptin Phosphate | 26 | $19,387 |
| XareltoRivaroxaban | 29 | $17,188 |
| Spiriva RespimatTiotropium Bromide | 23 | $16,812 |
| Tresiba Flextouch U-100Insulin Degludec | 21 | $15,135 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Synjardy, Spiriva Respimat, Tradjenta, Combivent Respimat | $282 | $265,127324 claims |
| Novo NordiskOzempic, Rybelsus | $173 | $87,00579 claims |
| PfizerEliquis, Effexor Xr | $222 | $83,671112 claims |
| MerckJanumet, Januvia | $18 | $78,25378 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $584 | $68,092113 claims |
| Johnson & JohnsonInvega Sustenna, Xarelto | $205 | $57,50641 claims |
| AstraZenecaFarxiga, Brilinta | $261 | $52,31656 claims |
| Lilly USA, LLCTrulicity | $150 | $30,10030 claims |
| AbbVieLinzess | $344 | $24,11830 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,087 medical providers in California.
Other medical in Escalon
- Nicola LowreyOrange$655K
- Justin LoveLoma Linda$553K
- David DoriguzziLancaster$514K
- Alison GracomIrvine$467K
- Jeffrey BonnaudLos Angeles$314K
- Ana TorresLaguna Beach$229K
- Heather ParlettRedlands$168K
- Deirdre MoxleyFullerton$149K
- Tri leGardena$127K
- Linda RankLadera Ranch$105K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.